A phase II study of capecitabine and Lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network Study

Journal of Gastrointestinal Oncology

Volumn 3, Issue 2, 2012, Pages 90-96

  Frank, Daniel ^a   Jumonville, Alcee ^b   LoConte, Noelle K ^c   Schelman, William R ^c   Mulkerin, Daniel ^c   Lubner, Sam ^c   Richter, Katie ^c   Winterle, Natalie ^c   Wims, Mary Beth ^c   Dietrich, Leah ^b   Winkler, J Mitchell ^e   Volk, Michael ^e   Kim, KyungMann ^c,d   Holen, Kyle D ^c  

^a University of Wisconsin Health   (United States)

^b Gundersen Lutheran Health System   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Green Bay Oncology   (United States)

Author keywords

Capecitabine; Colorectal cancer; Egfr; Her 2; Lapatinib

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; CAPECITABINE; FLUOROPYRIMIDINE; IRINOTECAN; LAPATINIB; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BEDTIME DOSAGE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL STUDY; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECTUM CARCINOMA; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84995775947     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2011.049     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts & Figures 2003. Atlanta, GA: American Cancer Society, 2003.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated f luorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
6. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
7. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
8. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
10. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
12. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 2004;4:262-7.
13. Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006;94:1136-43.
14. Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, Grossbard M. Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 2009;8:38-42.
15. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous f luorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
16. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-43.
17. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
18. Budman DR, Soong R, Calabro A, Tai J, Diasio R. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs 2006;17:921-8.
19. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
21. Fields AL, Rinaldi DA, Henderson CA, Germond CJ, Chu L, Brill KJ, et al. An Open-Label Multicenter Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Patients with Metastatic Colorectal Cancer. ASCO Annual Meeting Proceedings 2005;23:s3583.